Compare EUDA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | LUNG |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 72.2M |
| IPO Year | N/A | 2020 |
| Metric | EUDA | LUNG |
|---|---|---|
| Price | $12.37 | $1.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $55.00 | $5.38 |
| AVG Volume (30 Days) | 160.2K | ★ 727.7K |
| Earning Date | 12-19-2023 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $134.73 | $2.48 |
| Revenue Next Year | $195.03 | $18.46 |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.33 | $1.28 |
| 52 Week High | $11.47 | $7.05 |
| Indicator | EUDA | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 95.59 | 33.99 |
| Support Level | $1.66 | N/A |
| Resistance Level | N/A | $1.93 |
| Average True Range (ATR) | 0.77 | 0.11 |
| MACD | 1.31 | -0.04 |
| Stochastic Oscillator | 74.74 | 0.79 |
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.